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Thyroid cancer is the most common endocrine malignancy. Despite having a good progno-
sis in the majority of cases, when the tumor is dedifferentiated it does no longer respond
to conventional treatment with radioactive iodine, the prognosis worsens significantly.
Treatment options for advanced, dedifferentiated disease are limited and do not cure the
disease. Autophagy, a process of self-digestion in which damaged molecules or organelles
are degraded and recycled, has emerged as an important player in the pathogenesis of
different diseases, including cancer. The role of autophagy in thyroid cancer pathogenesis
is not yet elucidated. However, the available data indicate that autophagy is involved in sev-
eral steps of thyroid tumor initiation and progression as well as in therapy resistance and
therefore could be exploited for therapeutic applications. The present review summarizes
the most recent data on the role of autophagy in the pathogenesis of thyroid cancer and
we will provide a perspective on how this process can be targeted for potential therapeu-
tic approaches and could be further explored in the context of multimodality treatment in
cancer and personalized medicine.
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INTRODUCTION
Thyroid carcinoma (TC) is the most common endocrine malig-
nancy accounting for >90% of malignancies of endocrine glands
(1). Worldwide, the incidence of TC has increased, which can be
explained by the more intensive use of imaging modalities that
increased the detection of small, non-symptomatic tumors (2).
Differentiated thyroid carcinoma (DTC), which is the most preva-
lent TC, has an excellent 10-year prognosis of around 85% (3).
Effective treatment in most DTC patients consists of total thy-
roidectomy followed by therapy with radioactive iodide (RAI),
which is based on the unique ability of follicular thyroid cells to
take up iodine via the sodium-iodide symporter protein (NIS)
(4). Although prognosis of DTC is favorable, unfortunately, in a
high proportion of patients with metastases, the capacity for RAI
accumulation is diminished or lost.
THYROID CANCER PATHOLOGY AND MOLECULAR
PATHOGENESIS
Thyroid carcinomas are categorized into three groups. DTC (97%)
and anaplastic thyroid carcinoma (ATC) (1%) originate from fol-
licular epithelial cells, whereas medullary thyroid carcinoma (2%)
(MTC) originates from neuroendocrine parafollicular cells. DTC
can be distinguished in many histological subtypes, major groups
being papillary thyroid carcinoma (PTC), which is the most com-
mon type of TC (87%), and follicular thyroid carcinoma (FTC)
(6%). Hürthle cell carcinomas (3–4%) form a distinct subgroup
of DTC that are mostly FTC but can also be PTC. Mixed FTC and
PTC also occur.
The genetic events involved in DTC include several gene
rearrangements and gene mutations. As a consequence of these
genetic mutations and/or rearrangements, signaling pathways are
activated in favor of cell growth, survival, and angiogenesis.
PTC frequently harbor point mutations of BRAF (30–69%) and
rearrangements in the RET oncogene (40–70%) leading to MAP-
kinase pathway activation (5–8). To a lesser extent, RAS gene
mutations also occur in PTC (10–20%). FTC frequently harbor
RAS mutations (18–52%) and/or PPARγ/PAX8 rearrangements
(25–56%) (9). Mutations of PTEN may also be present in FTC.
RAS mutations constitutively activate both MAPK and PI3K/AKT
signaling pathways. Genetic alterations involving the PI3K/AKT
signaling pathway are rare in DTC. In ATC, genetic alterations in
the PI3K/AKT signaling pathway may be present (10–12). Also,
mutations of the p53 tumor suppressor gene (13) are involved.
Recently, mutations in the β-catenin gene have been described in
TC (13–16).
DEDIFFERENTIATION
Differentiated thyroid carcinoma initially retains the biological
properties of normal thyroid cells [iodide uptake by NIS, thy-
roglobulin (Tg) synthesis, expression of thyroid peroxidase (TPO),
and receptor for thyrotropin (TSHR) (17–19)]. However, NIS,
TPO, Tg, and TSHR expression gradually decrease in DTC with
NIS and TPO disappearing at an earlier stage than others (20–23).
Most studies showed reduction or even absence of NIS mRNA in
TCs (24–26), while immunohistochemistry studies have demon-
strated that NIS protein is overexpressed in many thyroid tumors
and is predominantly located in the cytoplasm (17, 21, 24). TSHR
expression is persistent in nearly all DTC (21, 24, 27–29). Tg pro-
duction remains preserved even in absence of iodide uptake. In
ATC, Tg secretion may decrease and is eventually lost (21, 24,
27, 29). A causal relationship between genetic alterations and loss
of functional NIS expression is present: tumor cells harboring
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BRAFV600E mutation have decreased NIS, TPO, and TSHR gene
expression compared to other tumor cells without this mutation
(24, 30–34). In addition, a relationship between activation of PI3K
and mammalian target of rapamycin (mTOR) and loss of NIS
expression has also been described (35).
INITIAL THERAPY
According to the consensus of the American Thyroid Association
(ATA) (36, 37), with the exception of small unilateral PTC, most
patients with DTC should be subjected to initial therapy consist-
ing of near-total thyroidectomy followed by RAI remnant ablation
therapy. In recent years, the benefits of RAI ablation therapy are
debated and a strategy based on risk of recurrence is recommended
(37). Recent landmark studies (ESTAMIBL and HiLo) have indi-
cated that 37 mCi is as efficacious as 100 mCi for thyroid remnant
ablation (37–39).
RECURRENT OR PERSISTENT DISEASE
When a malignant lesion is accessible, surgery can be performed.
If a malignant lesion is present, which cannot be cured by
surgery, RAI therapy may be performed. The remission rate
in pulmonary metastases treated with RAI varies from 90% in
patients with microscopic metastases to 10% in macroscopic
metastatic disease and from 20 to 7% in bone metastases (37,
40, 41). Palliative therapies include external irradiation, radiofre-
quency ablation, chemoembolization and for pulmonary metas-
tases, endobronchial laser therapy (42–45). Approximately 5–15%
of DTC patients will develop or present with local recurrent dis-
ease or metastasis. In 25–66% of these patients, the susceptibility
to RAI is diminished or lost (3, 37, 46).
Treatment options for patients with RAI resistance were
until recently limited to palliative treatment, as conventional
chemotherapy is not effective in DTC. Recently, novel treatment
options have become available in terms of kinase inhibitors (KIs).
The DECISION trial, with sorafenib, was the first phase III
study with a kinase inhibitor in DTC (46) and showed a reduction
in progression free survival (PFS) of 5 months. A phase III study
with lenvatinib (SELECT study) showed a reduction in PFS of
14.7 months (47). In addition to multi-kinase inhibitors (MKI),
compounds have been developed the selectively target mutated
kinases. Both studies have shown for the first time that MKI have
a benefit on PFS in patients with advanced DTC. However, these
drugs are only effective in subgroups of patients and most effects
are temporary. Therefore, additional approaches are warranted.
Study of pathogenetic mechanisms in DTC may reveal novel tar-
gets for therapy. Autophagy has emerged during the last years as
an important player in the pathogenesis of TC.
AUTOPHAGY AND CANCER
An increasing body of literature supports the central role of
autophagy in cancer development from initiation to progres-
sion and metastasis, including TC. Autophagy (“self-digestion”) is
an evolutionarily conserved mechanism present in all eukaryotic
cells, essential for maintaining cell homeostasis and adaptation
to various stress situations including metabolic and oxidative
stress resulting from nutrient deprivation or hypoxia (48). In this
process, in conditions of cellular stress often resulting in exces-
sive production of damaged proteins or organelles and reactive
oxygen species (ROS), a double layer membrane is generated
in the cytoplasm that engulfs defective or toxic molecules and
organelles to form an autophagosome. After fusion with the lyso-
somes and release of lysosomal acid enzymes in the vesicle, these
molecules undergo enzymatic digestion and the resulting products
are either removed from the cells or are made available for syn-
thesis of new proteins or organelles. This process is also known as
macroautophagy (henceforth referred to as“autophagy”). In addi-
tion to macroautophagy, microautophagy has also been described,
referring to the process of self-digestion in which no autophago-
some is formed and the molecules compelled for degradation
are engulfed by the lysosomes through invagination of lysosomal
membrane. Furthermore, soluble proteins can be shuttled into the
lysosome via the lysosomal chaperone proteins, a process termed
chaperone-mediated autophagy (48).
Autophagy involves several Atg (autophagy) proteins, encoded
by ATG genes. The function and the structure of these proteins
have been initially and extensively studied in yeast species (49).
However, for the majority of these proteins human orthologs have
been found as well. A schematic representation of the process of
autophagy is presented in Figure 1. The regulation of autophagy is
very complex and not completely understood. One of the central
molecules involved in the regulation of autophagy is the mTOR,
which is a very potent inhibitor of autophagy (50). Moreover
mTOR is involved in a complex network of signaling pathways that
control and link a number of other fundamental cellular processes
including cell metabolism, differentiation, proliferation, and cell
survival (51, 52). The mTOR kinase activates multiple pathways
that favor cellular proliferation and inhibits the autophagy path-
way, thereby preventing cell cycle arrest. Furthermore, mTOR
induces a metabolic shift toward glycolysis in both aerobic and
anaerobic microenvironments, also known as the Warburg effect,
to enable proliferation at higher rates and in hypoxic conditions,
respectively (53).
Several studies link autophagy to cancer. It has been shown
that autophagy can have either a positive or a negative effect on
cancer development and progression depending on tumor type
and stage of the disease. This apparently dual position is not com-
pletely understood but it seems to reflect the complex effect of
autophagy on several fundamental processes such as cell survival,
cell death, senescence, cellular metabolism, and inflammation in
the context of continuous external changes in the tumor microen-
vironment. The role of autophagy in TC is largely unexplored.
The evidence is only scarce and fragmented. Nevertheless, there
are clear indications that autophagy is involved in several steps
of thyroid tumorigenesis and progression as well as in therapy
resistance and therefore could be exploited for therapeutic appli-
cations. In the present review, we will summarize the most recent
data on the role of autophagy in the pathogenesis of TC and we
will provide a perspective on how this process can be targeted for
potential therapeutic approaches in TC.
AUTOPHAGY AND TUMOR INITIATION
In basal conditions, autophagy is fundamentally involved in
maintaining the cellular homeostasis. In pathological conditions
inducing cellular stress, autophagy is upregulated primarily for
cytoprotective purposes. In this case, incapacity of the cells to
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FIGURE 1 | Molecular machinery of autophagosome assembly and
lysosomal fusion. Beclin 1 is part of the type III PI3K complex that initiates
autophagosome formation. Two ubiquitin-like systems are required for
formation of the isolation membrane; (I) coupling of LC3 (ATG8) to
phosphatidylethanolamine (PE) and (II) conjugation of ATG12 to ATG5 and
ATG16L1. The five C-terminal amino acids of LC3 (unconjugated LC3-I) are
cleaved of by ATG4, which is required to link the protein after activation by
ATG7 and ligation by ATG3 to PE in the autophagosomal membrane
(conjugated LC3-II). Similarly, ATG7 and ATG10 couple ATG12 to ATG5 and
ATG16L1. This complex then localizes to the outer membrane of the forming
autophagosome. Autophagosomes then fuse with lysosomes for degradation
of their cargo.
upregulate autophagy, for instance, due to defective ATG genes,
can result in accumulation of defective molecules or excessive ROS,
which impair the function of cells and DNA stability resulting in
disease (54).
Several mechanisms have been suggested through which
autophagy might exert its tumor suppressive effects. Autophagy
has a crucial role in maintaining DNA stability. As a result of
oncogene activation, defective organelles produce high amounts
of ROS, which when accumulated in large amounts induce oxida-
tive stress and contribute to additional DNA damage. Autophagy
represents the major buffer mechanism activated to counteract
this excessive ROS production by removal of defective organelles
such as mitochondria as a main source of excessive ROS through a
process of selective mitophagy. In addition, autophagy contributes
to the quality control of the protein synthesis. Related to this,
autophagy has an important role in the clearance of defective
p62, a ubiquitin-binding protein that is produced in response to
metabolic stress. It has been shown that tumor cells in which the
autophagy mechanism is defective accumulate excessive amounts
of p62, sufficient to cause dysregulations of NF-kB signaling, accu-
mulation of ROS and DNA damage (55). Several studies suggest
that in the early phases of cancer development autophagy fulfills
primarily a tumor suppressive role.
Beclin 1, encoded by the BECL1 gene located on chromosome
17q21, is a key molecule involved in the initiation of autophagy
and phagophore formation. Previous studies have shown that in
autophagy-deficient mice due to monoallelic deletion of BECL1
develop spontaneously malignant tumors (56). Therefore, BECL 1
is considered as a haplo-insufficient tumor suppressor gene. More-
over, somatic monoallelic deletions of BECL1 stimulate develop-
ment of Hepatitis-B-induced premalignant liver lesions (56). In
addition to that, monoallelic deletions of BECL1 have been found
in a significant percentage of human cancers, including breast
cancer, melanoma, ovary, and prostate (57–60). Furthermore, an
increased Beclin 1 expression has been associated with a favor-
able prognosis in several cancers (60–62). In TC, however, Li et al.
have found by immunohistochemistry in samples from 86 patients
with PTC (57 with lymph node metastases) that Beclin 1 expres-
sion was increased in 88% of the PTC tissue samples and in 98%
metastatic lymph nodes whereas in the paired normal thyroid tis-
sues and lymph nodes without metastases from the same patients
the expression of Beclin 1 was only low or absent (63). The authors
suggest that Beclin 1 neo-expression correlate with the tumorige-
nesis and lymph node metastasis in TC. However, the mutation
status of the tumors is not mentioned in this study though may
be relevant for the interpretation of these data. It is known that
up to 75% of PTCs carry somatic mutations in the BRAF gene,
in particular the V600E BRAF (5–8). Presence of BRAF muta-
tions has also been associated with an increased risk for lymph
node metastasis in PTC. Furthermore, it has been shown that
in melanoma, BRAF mutations induce autophagy (64). There-
fore, whether the observed increased expression of Beclin1 and
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possibly the activation of autophagy in the study of Li et al. is the
cause or the consequence of the malignant process, it is not clear.
In addition, it has to be mentioned that the function of Beclin
1 is complex and reaches beyond autophagy, including the link
between autophagy and apoptosis (65,66). Therefore,although the
exact role of Beclin1 in the development of TC is not known, these
data suggest that autophagy is involved in the pathogenesis of TC.
Besides Beclin1, other autophagy-related proteins such as
Atg4c, Atg5, and Atg7 also were found to have tumor suppres-
sor functions in mice models and mutations autophagy-related
genes such as ATG2B, ATG5, ATG9B, ATG 12, and UVRAG have
been described in gastrointestinal cancers as well (67, 68). Further-
more, mice lacking Parkin, which is important for the ubiquitina-
tion of proteins on mitochondria contributing to the initiation
of selective autophagy of damaged mitochondria, show a pro-
carcinogenic phenotype (69, 70). With respect to TC, a recent
study suggests that patients carrying the ATG5 single nucleotide
polymorphisms rs2245214 have a higher probability to develop
TC. However, no other ATG genetic variants investigated in this
study showed a significant association with TC susceptibility. Fur-
thermore, none of the selected genetic variants were associated
with clinical parameters of disease progression and outcome (71).
Altogether, these studies support in part a tumor suppressive
role of autophagy at least in some tumor types. In this setting, one
might speculate that pharmacological induction of autophagy at
least in some autophagy-deficient cells might be beneficial in the
early stages of carcinogenesis. Nevertheless, none of the previous
studies has established a clear causal relationship between deficient
autophagy and tumorigenesis. Interestingly, other autophagy-
deficient mouse models, such as the Ulk1- or Nix-deficient mice
have not been shown to have an increased risk of spontaneous
malignancies (72, 73). Others, such as the FIP200-deficient mice
that lack an important autophagy gene have an impaired tumori-
genesis (74). Moreover, Beclin1 deficiency is often associated with
p53 deficiency suggesting that the function of these two proteins
is interrelated (59). Therefore, although autophagy may play an
important role in tumor initiation, this is not the only mechanism
involved in this process and its effect probably depends on the
integrity and activation of other biological processes as well, such
as apoptosis.
Another mechanism through which autophagy may be involved
in tumorigenesis involves its regulation by other oncogenes and
tumor suppressor genes. Figure 2 depicts the main pathways
involved in thyroid carcinogenesis and their link with autophagy.
Oncogenes such as Akt and class I PI3K inhibit autophagy whereas
tumor suppressor genes such as PTEN and p53 can stimulate
autophagy. Interestingly, germ-line mutations in PTEN cause a
syndrome characterized by increased risk to develop malignant
tumors including follicular thyroid neoplasia and FTC (75). Sev-
eral somatic mutations that play an important role in thyroid cell
malignant transformation can influence autophagy either posi-
tively or negatively. BRAF mutations that can be found in the
majority of PTC are known to activate autophagy in melanoma
(76) but possibly also in PTC (77). On the other hand, activation of
PI3K/Akt/mTOR pathway (78), which has been found to be more
common in ATC than in DTC (79) as well as in more aggressive
tumors (80, 81), sometimes in combination with BRAF or RAS
FIGURE 2 |The main pathways involved in the pathogenesis of thyroid
cancer and their effect on autophagy. Oncogenes such as Akt and class I
PI3K inhibit autophagy whereas tumor suppressor PTEN and p53 can
stimulate autophagy. BRAF mutations that can be found in the majority of
PTC activate autophagy.
mutations (79) is associated with inhibition of autophagy. Also,
inactivating mutations in the PTEN tumor suppressor gene lead-
ing to activation of the PI3K–Akt pathways have been found more
often in advanced TC (82). This data suggest that in TC, they may
represent late events resulting in progression to more aggressive
forms. Through its position at the crossroads between the MAPK
and the PI3K/Akt/mTOR pathway, RAS can play a dual role in the
regulation of autophagy. It can either stimulate autophagy when
the MAPK is selectively activated or inhibit autophagy through
activation of PI3K pathway. Therefore, when the autophagy
machinery is intact, the role of autophagy as a tumor suppressor or
tumor promotor may depend apart from the histological tumor
type also on the presence of certain mutations in oncogenes or
tumor suppressive genes and/or the accumulation of mutations in
the tumor during cancer development and progression.
AUTOPHAGY AND TUMOR PROGRESSION
Once the carcinogenic phenotype has been established, autophagy
plays a role in maintaining the malignant phenotype and in tumor
progression through its effect on cell metabolism, cell survival,
and cell death on one hand, and on the immune response in
the tumor microenvironment on the other hand. In other words,
the role of autophagy in tumor progression is largely depen-
dent on the crosstalk between autophagy and other fundamental
biological processes of apoptosis, senescence, immune response,
and inflammation. The rapidly multiplying tumor cells rely on
autophagy to maintain an increased proliferation rate in an unfa-
vorable microenvironment characterized by hypoxia, insufficient
nutrients delivery, and oxidative stress. As a result of these unfa-
vorable conditions or as a direct effect of the oncogenic mutations,
tumor cells switch for their energy metabolism to aerobic glycolysis
(Warburg effect). Interestingly, as shown above, the same muta-
tions, such as PI3k/Akt/mTOR, also inhibit the autophagy. In the
context of restrictive nutrients delivery, this deficient autophagy
can result in apoptotic-deficient tumor cells in increased cell death
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through necrosis due to the fact that the cancer cells are unable
to meet the increased metabolic energy demands (83). In contrast
to apoptotic cells, cells that die through necrosis, through rup-
tures of their plasma membrane, release several proinflammatory
molecules, the damage-associated molecular patterns (DAMPs),
such as uric acid, ATP/UTP, high mobility group B1 (HMGB1), in
their microenvironment. These molecules help recruit and activate
macrophages and other antigen presenting cells, such as dendritic
cells (DC), and trigger adaptive immune responses and cytokine
production that create a pro-tumorigenic environment in the per-
itumoral stroma, which can result in angiogenesis, tumor progres-
sion, and metastasis. In addition, both antigen presentation and
antigen recognition that represent the cornerstone of this immune
response are dependent on the integrity of the autophagy machin-
ery. In this respect, it has been shown that autophagy facilitates
antigen presentation by tumor cells, such as human embryonic
kidney cells (HEK293T) and melanoma cells, thereby facilitating
the recognition of these cells by the immune system, facilitating
the removal of these cells (84). Another mechanism through which
autophagy, through crosstalk with inflammation, can contribute
to tumor progression is by facilitating the cellular senescence. In
this process, senescent cells that are characterized by a sustained
cell arrest produce cytokines that promote recruitment of immune
cells that are ultimately responsible for the removal of the senescent
cells but also can facilitate the tumor progression (85). Therefore,
in addition to its role in maintaining the metabolic homeostasis,
cellular integrity and function, and in cell survival and cell death,
autophagy contributes to shaping the immune response in the
tumor microenvironment.
The tumor necrosis factor (TNF) family comprises sev-
eral ligands, among which TNF-related apoptosis-inducing lig-
and (TRAIL), which trigger apoptosis and has been shown
to potently and selectively kill TC cells (86). Investigation of
TRAIL has attracted attention in cancer therapy studies because
they contribute to the immune cell-mediated cytotoxicity and
because recombinant ligands are available for pharmacological
use. Nonetheless, treatment with TRAIL has been hampered with
significant therapy resistance in several cancers, including TC. It
has been shown that T-helper 1-type cytokines, such as interferon
(IFN)-gamma, TNF-alpha, and IL-1 beta increase the sensitivity of
both normal and neoplastic thyrocytes to TRAIL. However, IGF-
I and other growth/survival factors produced in the local tumor
microenvironment activate the PI3K/Akt pathway, exert an anti-
apoptotic effect, and are also known to inhibit autophagy through
mTOR (86, 87). Recently, Jin et al. has shown that in PTC cell line
TPC-1 harboring RET/PTC1 rearrangement, TRIAL treatment
induced activation of autophagy and apoptosis whereas block-
ing autophagy using ATG7 siRNA abrogated this effect (88). In the
same study, in the ATC cell line FRO, treatment with TRAIL did
not induce the autophagy and blocking the autophagy with ATG
siRNA sensitized FRO cells to TRAIL-induced apoptosis. There-
fore, both the PTC and the ATC might benefit from modulation
of autophagy. However, depending on the type of tumor and the
mutation status of the tumor, either stimulation or inhibition of
autophagy may be beneficial.
To add to the complexity of the role of autophagy in cell death, it
has been shown that despite its primary cytoprotective functions in
response to various forms of stress in normal cells, when activated
excessively, it is believed that autophagy can contribute to cell
death. In this case, it has been suggested that, uncontrolled exces-
sive autophagy, such as results from overexpression of Beclin1 in
mammalian cells (89), might result in cell death through either
stimulation of apoptosis (90) or massive uncontrolled, possibly
selective, self-digestion of cytoplasmic components beyond repair
that render the cell unviable (91). Clearly, several arguments sup-
port the link between autophagy and apoptosis. Both processes
share common regulatory pathways and effector molecules. Both
can exert an either positive or negative effect on each other and
sometimes activation of both may coexist in the same tumor. How-
ever, the majority of studies supporting the autophagy-dependent
cell death were performed in cells deficient in apoptosis (91),
suggesting that autophagy represents only a non-canonical path-
way leading to cell death. The exact regulatory mechanisms that
influence the equilibrium between apoptosis and autophagy and
ultimately determine cell fate, either cell death or survival, remain
elusive.
The results of a few recent studies support the role of
autophagy-dependent cell death in TC. Reversine, a synthetic
purine analog has been shown to induce apoptosis and cell cycle
arrest in differentiated and poorly differentiated TC both in vitro
and in vivo in mouse xenograft models (92). Lu et al. (93) showed
that reversine was also able to induce phagosome formation in
WRO cells in a dose-dependent manner possibly through the
Akt/mTOR/p70S6K pathway that was suppressed after exposure
to reversine. Another argument to support the crosstalk between
autophagy and apoptosis is provided by the studies on the anti-
tumoral effects of statins. Zeybek et al. showed that in PTC
and normal thyroid cell lines treatment with rosuvastatin, the
statin inhibited the cell proliferation and induced cell death in
a dose-dependent manner. In this study, autophagy was partic-
ularly activated in the BC-PAP cell line (BRAF V600E positive)
at lower doses whereas at higher doses induction of apoptosis
was predominant (94). Furthermore, Lopergolo et al. investigated
whether the combination therapy with the RET-targeting tyrosine
kinase inhibitor sunitinib and cisplatin can enhance apoptosis in
MTC cell lines harboring the RET M918T oncogene and xenograft
mouse model (95). The authors found that sunitinib induced a
severe autophagosome accumulation and lysosomal dysfunction
and cisplatin induced additional lysosomal leakage. Combination
therapy resulted in more apoptotic cell death and a better response
in xenograft mouse model with MTC.
The relation between cancer cell metabolism and its impact on
cell survival, proliferation, and autophagy in TC has only scarcely
been studied. In a recent study, Morani et al. have investigated the
impact of PTEN deficiency and mutant p53 on glucose metabolism
in two TC cell lines, the FTC133 (PTEN null, p53 mutated) and
WRO (wild type p53 and PTEN). They have found that the FTC133
cell line that display impaired apoptosis and reduced autophagy
due to the somatic mutations in PTEN and p53 were clearly more
sensitive to glucose restriction than the WRO cells in which glu-
cose deprivation was able to stimulate autophagy and therefore
offer the cells an escape route to prolonged survival (96). This
is clearly in line with the other studies showing that in apop-
tosis, deficient tumor cells that are depending for the increased
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energy requirements on an increased influx of glucose for glycol-
ysis, maintaining an intact or an increased autophagy response
is crucial for cell survival in conditions of nutrients deprivation.
Defects in autophagy, such as those resulting from concomitant
mutations in the PTEN or PI3K/Akt pathway render the cells more
sensitive to glucose depletion. This phenomenon could potentially
be explored for therapeutic tumor starvation strategies in TC.
AUTOPHAGY AND TUMOR INVASION AND METASTASIS
The role of autophagy in tumor invasion and metastasis is less
known. The epithelial-to-mesenchymal transition (EMT) repre-
sents an important step to invasion and metastasis. In this process
that enables detachment of the cells from their natural environ-
ment tumor cells gain properties including enhanced plasticity
that favors survival and metastasis and induce resistance to cyto-
toxic agents and radiotherapy. In this context, it has been found
that autophagy is involved in the regulation of cell plasticity (97).
In addition, it helps preventing anoikis (cell death after the cell
has been detached from its extracellular matrix) and therefore
promoting survival of cells that have been detached form their
extracellular matrix (98). Furthermore, induction of autophagy
in breast carcinoma cells has been shown to induce EMT and
resistance to cytotoxic T-cell-mediated lysis, therefore targeting
autophagy may potentially avoid the occurrence of this resistance
(99). Interestingly in this context, Meng et al. reported recently that
knockdown of BAG3, a protein involved in multicellular pathways,
induces EMT in thyroid cells through activation of a E-cadherin
suppressor, ZEB1 (100). Furthermore, BAG3 has been found to
be involved in Beclin1-independent autophagy (non-canonical
autophagy) (101). Li et al. found that Earle’s balanced salt solution
(EBSS) starvation reduced the BAG3 expression in vitro in thy-
roid cells and that forced BAG3 expression suppressed autophagy
and promoted the apoptosis in TC cells exposed to EBSS star-
vation, making the BAG3 an interesting potential target to be
further explored for therapy (102). In another recent publication,
Wang et al. have investigated the effects of long non-coding DNA
(lncRNAs) on TC cells in vitro (77). The BRAF-activated lncR-
NAs (BANCR), which are novel regulators implicated in cancer
biology, have also been shown to be overexpressed and involved
in cell migration in melanoma. BANCR has also been shown to
induce EMT in malignant tumors such as melanoma, colon can-
cer, and non-small cell lung cancer (103–105). The BANCR were
overexpressed in four of the five investigated tissue samples of
PTC and in IHH-4 PTC cell line compared to the normal thyroid
tissue. Overexpressed BANCR markedly activated autophagy and
inhibited apoptosis in the PTC cell line. Inhibition of autophagy
abrogated the effects of BANCR on cell proliferation. In this study,
there were no evident effects of BANCR on the cell migration in the
TC cells. Therefore, although some studies suggest that autophagy
may play a role in tumor invasion and metastasis, its place in the
pathogenesis of TC is not well defined. Further studies to elucidate
this process may uncover novel therapeutic strategies.
AUTOPHAGY AND RESPONSE TO THERAPY
Several studies have implicated autophagy in the tumor response
and resistance to therapy with either ionizing radiation or other
cytotoxic agents. It has been shown that treatment with ionizing
radiation is associated with a strong induction of autophagy and
this may contribute to cell survival and the acquired resistance
to therapy in many cancer cells including breast, nasopharyn-
geal, pancreatic cancer, and malignant glioma (106–110). For this
reason, inhibition of autophagy with chloroquine or hydroxy-
chloroquine in combination with radiotherapy or chemotherapy
has been investigated as a strategy to prevent therapy resistance
and sensitize tumors to therapy. This, however, does not seem to
be the case in TC. Yeung et al. published in 2007 the first obser-
vation on autophagy and TC in relation to therapy (111). In this
study, the authors observed in a mouse xenograft model obtained
with ARO and KAT4 ATC cell lines increased macroautophagy in
the tumors from the mice treated with the antiangiogenic agent
Combretastatin A4 phosphate. The authors suspected that this
is likely explained by the induction of autophagy due to anoxia
and starvation resulting from therapeutic vascular disruption in
this model. A few years later, Lin et al. found that doxorubicine
and radiation also induced autophagy in both human PTC sam-
ples and PTC cell lines (112). However inhibition of autophagy
with 3-methyladenine (3 MA) decreased the radiosensitivity and
chemosensitivity of the TC cells, suggesting that at least for the
therapy resistant PTC stimulation of autophagy may be a poten-
tial therapeutic strategy. In line with this hypothesis, Lin et al.
showed that stimulation of autophagy using the mTOR-inhibitor
everolimus resulted in sensitization of PTC cells to both doxoru-
bicin and radiation. Furthermore, the effects of everolimus and
doxorubicin as radiosensitizers were synergistic. The authors sug-
gest that the autophagy-dependent cell death, as detailed in the
previous paragraph, mediated through Met kinase is the main
mechanism behind these effects (113). Treatment with everolimus
has also been shown to potentiate the activity of sorafenib and
sunitinib, two MKI that target particularly the VEGF and the
MAPK in MTC through induction of autophagy (114). There-
fore, in contrast to other cancer, although treatment with both
chemotherapy and radiotherapy were shown to induce autophagy
in TC cells, the TC seem to profit from the synergistic activation
of autophagy, possibly through mechanisms related to autophagic
cell death to increase their sensitivity to the cytotoxic agents.
Radiotherapy and chemotherapy also induce oxidative stress
and result in cell death. Interestingly, autophagy has been shown
to play an important role in the response to chemotherapy of some
tumors, in particular through influencing the immune response
in the tumor microenvironment. It is known that treatment with
chemotherapy can induce immunogenic cell death. In other words,
as a result of treatment with chemotherapeutic agents, a succes-
sion of processes takes place resulting in apoptosis and necrosis.
As a consequence, membrane exposure of calreticulin and release
of other proteins such as HMGB1 and ATP takes place that in
turn have the ability to attract and recruit antigen presenting
cells such as macrophages and DC in the tumor microenviron-
ment. The DCs engulf the damaged tumor cells (remnants) and
through antigen-presentation activate T-cells that in turn exert
an antitumoral effect on the remaining unaffected cancer cells,
thus enhancing the antitumoral effect of the chemotherapeutic
agent. In TC, it has been reported that treatment with selume-
tinib and IFN gamma increased the immunogenicity of PTC cell
through increased HLA-ABC expression and was associated with
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increased T-cell activation and IL2 production by peripheral blood
leukocytes co-cultured with treated PTC cell lines (115). Michaud
et al. has shown in cell lines and mouse models that particu-
larly the ATP release by the chemotherapy-induced dying tumor
cells is highly dependent on the integrity of autophagy and is
required to induce an antitumoral immunogenic response (116).
In this study, autophagy-deficient tumors released significantly
lower amounts of ATP and were not able to elicit antitumoral
immunogenic responses in response to therapy with methotrex-
ate. The immunogenicity of the autophagy-deficient cells could
be restored when treated with ARL67156, an inhibitor of ecto-
ATPases that increased the extracellular ATP concentrations and
when treated with recombinant human IL-1β, whose production
depends on the availability of ATP. Furthermore,when treated with
methotrexate in vivo in immunocompetent mice, only the growth
of autophagy-competent tumors could be reduced as compared
to the autophagy-deficient tumors. In contrast, there was similar
lack of response to treatment of these tumors in immunodefi-
cient mice, regardless the autophagy status. This suggests that the
immunogenic response is an essential contributor to the efficacy
of chemotherapy and that this response is highly dependent on
the integrity of the autophagy pathway.
Autophagy has also been linked to response to treatment
with proteasome inhibitors. Autophagy is closely related to the
ubiquitin-proteasomes system (UPS), the other main intracellular
protein degradation pathway within the eukaryotic cells (117).
Proteasome inhibitors, including the multipathway inhibitor
bortezomib, are promising agents for treatment of highly aggres-
sive cancer (118). Studies performed on several cancer cell lines
demonstrated that autophagy inhibitors can synergize with the
cytotoxic effects of the proteasome inhibitors (119–121). Based on
these preclinical data, a number of trials investigating autophagy
inhibition in combination with proteasome inhibitors have been
initiated. In TC, Zhang et al. found that proteasome inhibitors
induced a decrease in Beclin 1 expression (122). However, the
exposure to proteasome inhibitors caused beclin 1-independent
macroautophagic cytotoxic responses in TC cells. In this context,
in TC cells Beclin 1 was able to potentiate the antitumoral effects of
the proteasome inhibitors in an autophagy-independent manner
via survivin and suppressin.
An important mechanism contributing to therapeutic resis-
tance of cancer cells involves activation of pathways that confer
stem cell-like characteristics onto cancer cells (123, 124). This
process is strongly linked to EMT, which promotes cell survival
and invasiveness, resulting in more aggressive tumor phenotype.
Recent studies suggest a link between the EMT, stem cell-like char-
acteristics, autophagy, and resistance to cytotoxic agents (97, 99).
Hinterseher et al. reported a clear expression of hedgehog pathway
signaling factors, which are involved in the survival of stem cells, in
two ATC cell lines (Hth 74, C643) and in primary tumor samples
(125). Moreover, treatment of these cell lines with the hedgehog
inhibitor cyclopamine showed a time- and dose-dependent inhi-
bition of cell growth. Activation of hedgehog pathway has also
been reported in MTC (126). Inhibition of hedgehog pathway
has been shown to activate autophagy (127). Therefore, exploring
how modulation of autophagy in this context may help prevent
therapeutic resistance is warranted.
Summarizing these data, modulation of autophagy has the
potential to synergize and contribute to the effect of other cyto-
toxic treatments and reduce resistance to treatment, which should
be further explored in the context of multimodality treatment in
cancer and personalized medicine.
IMPLICATIONS FOR THERAPY
IMPLICATIONS OF TARGETING AUTOPHAGY FOR THYROID CANCER
THERAPY: PRECLINICAL STUDIES
Genetic alterations in the PI3K/Akt/mTOR pathway cause an
addiction to this pathway in TC cells and create sensitivity to
inhibition by targeting players in this pathway, such as Akt and
mTOR (128). Among these, mTOR is of particular interest due to
its involvement in the control of cell proliferation. Inhibitors of
mTOR such as rapamycin, everolimus, and temsirolimus have all
been shown to inhibit tumor cell proliferation in several cellular
models. Rapamycin effectively inhibits proliferation and induces
apoptosis of SW579 cells. Furthermore, the invasive ability of
SW579 cells decreased when treated with rapamycin. In con-
trast, no obvious changes were observed in the expression of Akt
indicating that there might be a feedback loop effect by mTOR
inhibition (129).
RAD001 (everolimus) is an orally bioavailable inhibitor of
the mTOR pathway. Papewalis et al. demonstrated that RAD001
inhibits cell growth in ATC cell lines (130). Also temsirolimus,
a specific mTOR inhibitor showed the potency of suppressing
growth in several cell lines that harbored genetic alterations in
the PI3K/Akt/mTOR pathway with IC50 (concentration at which
50% inhibition occurs) in the nanomolar range (128).
Mammalian target of rapamycin exists in two different com-
plexes, mTORC1 and mTORC2, which could both be targeted
by potential anti-cancer agents. Rapamycin inhibits the mTORC1
complex, but not the mTORC2 complex (131). The general
view is that mTORC2 regulates Akt and, as a consequence of
only targeting mTORC1 activity, it has been shown that drug
resistance quickly develops due to compensatory activation of
Akt (132, 133). Therefore, it seems essential to target both the
mTOR complexes for desired anti-cancer effects (134). In the
last few years, several mTOR ATP-competitive inhibitors have
been reported acting upon mTOR in both complexes and show-
ing a more complete anti-cancer activity in comparison with
that of rapamycin and its derivatives (135). These new mTOR
inhibitors provide a method to avoid the feedback up-regulation
of p-AKT observed with mTORC1 inhibitors (136). For example,
INK128, a dual mTORC1 and mTORC2 kinase inhibitor, inhib-
ited growth at low nanomolar concentrations in cell lines and
5-week-old Tg-RET/PTC3 mice treated with 3 mg/kg for 2 weeks
displayed a reduced proliferation index (136). Treatment with
Torin2, another second-generation mTOR inhibitor, inhibited cell
viability and induced caspase-dependent apoptosis via activation
of mitochondrial apoptotic pathway in PTC cells. In addition,
on PTC xenograft tumor growth in nude mice Torin2 treatment
induces anti-cancer effects (137).
Another way to avoid the negative feedback loop in mTORC2 is
to directly inhibit Akt. KP372-1, an Akt inhibitor, blocked signaling
downstream of Akt in thyroid tumor cells, leading to inhibition
of cell proliferation and increased apoptosis. The major advantage
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of KP372-1 over Wortmannin and LY294002 as PI3K inhibitors
is its greater efficacy and the marked induction of apoptosis in
cancer cell lines. This may be due to its targeting a central down-
stream molecule and also due to the potential for a number of
processes to bypass effects at the level of PI3K (138). Moreover,
in vivo use of LY294002 in mice has been associated with many
adverse effects, including death (139). Similarly, Wortmannin has
demonstrated hepatic and hematopoietic toxicity (140). There-
fore, although Wortmannin and LY294002 inhibit the PI3K/Akt
pathway, their drawbacks raise concerns about their suitability as
leading candidates for further development as anti-cancer drug.
However, despite its greater efficacy, a potential downside of Akt
inhibitors is toxicity because of the importance of Akt signaling in
many normal cellular processes such as insulin signaling, and the
lack of selectivity of the current Akt inhibitors including KP372-1
to different Akt isoforms (138).
Over the years, several new and selective Akt inhibitors have
been developed. MK2206 is a recently developed novel non-ATP-
competitive allosteric Akt inhibitor. Liu et al. tested the therapeutic
potential of MK2206 for TC using various TC cells with known
genotypes in the PI3K/Akt pathway. They demonstrated its potent
and efficacious inhibition of proliferation with IC50 values in the
low micromolar range, mostly below or around 0.5µm,of TC cells
that harbored mutations in the PI3K/Akt pathway (141). Although
Akt inhibitors show effect in different cell lines, they are less potent
as a single-drug than mTOR inhibitors. A prior report demon-
strated that the presence of genetic alterations of PTEN, PIK3CA,
and Akt1 correlated well with sensitivity to an Akt inhibitor, but
had weaker correlations with the sensitivity to an mTOR inhibitor
(128). This discrepancy suggests that mTOR activity does not
depend solely on PI3K/Akt activity and may explain the lower
efficacy of Akt inhibitors in comparison with mTOR inhibitors.
IMPLICATIONS OF TARGETING AUTOPHAGY FOR THYROID CANCER
THERAPY: CLINICAL STUDIES
Novel small-molecule protein-KIs have shown promising results in
clinical trials on thyroid cancer, including axitibib (142), sorafenib
(143), motesanib (144), and pazopanib (145). These KI mainly
target the RAS–RAF–MEK–ERK pathway and prevent angiogene-
sis by inhibiting vascular endothelial growth factor receptors. KIs
that inhibit the PI3K/Akt/mTOR pathway are less common, but
the rapamycin analog everolimus, has recently been shown to have
potential in clinical trials.
Lim et al. (146) published the first clinical trial of the activity of
everolimus in patients with progressive, locally advanced or RAI
refractory TC including all histologic subtypes. The primary end
point was disease control rate, defined as partial response and sta-
ble disease ≥12 weeks. The patients self-administered everolimus
10 mg orally once daily until unacceptable toxicity or disease pro-
gression was reached. Disease control was observed in 31 (81%)
patients and the median PFS was 47 weeks in all patients. However,
a confirmed objective response was observed in only two patients
(5%). Another phase-II trial included patients with metastatic,
incurable RAI refractory, and progressive TC who were treated
with 10 mg everolimus orally, showed similar results (147). The
primary endpoint in this study was PFS. Only one patient experi-
enced a partial response, whereas 18 (55%) and 10 (30%) achieved
stable disease lasting 6 and 12 months, respectively. Interestingly,
activation of autophagy without markers of apoptosis was detected
in three patients subjected to sequential biopsies. It was concluded
that the activation of autophagy could account for the higher rate
of disease stability.
As KIs are known to induce stable disease only on a tempo-
rary basis, several mechanisms contribute to clinical resistance.
Carracedo et al. showed that mTORC1 inhibition can activate
MAPK through a PI3K-dependent feedback loop in human cancer
(148). Activation of a different prosurvival signaling pathway upon
mTOR inhibition explains as to why the tumor shows an initial
response followed by rapid progression. However, the majority of
known mechanisms of clinical resistance involve secondary muta-
tions in the target kinase. Such mutations have been described for
ABL, KIT, EGFR, ALK, BRAF, MEK, PDGFRA, FLT3, and ROS1
(149). Recently, evidence was obtained that acquired resistance to
mTOR inhibition can occur through these mechanisms (150).
Autophagy inhibition using hydroxychloroquine and other
autophagy regulators in combination with different therapeu-
tic strategies has been evaluated in early-phase clinical trials on
various types of tumors (151, 152). Chloroquine and hydroxy-
chloroquine inhibit autophagy at a late stage by blocking lysosomal
acidification resulting in an inability to digest its engulfed cargo.
This leads to increased cytotoxicity in combination with several
anti-cancer drugs in preclinical models. These results led to multi-
ple early-phase clinical trials in humans, mainly with solid tumors
(151, 152). Although targeting autophagy in cancer will provide
new opportunities for drug development, more potent and spe-
cific inhibitors of autophagy are needed. Moreover, the effect of
autophagy regulators in TC should be further evaluated.
IMPLICATIONS OF TARGETING AUTOPHAGY FOR THYROID CANCER
THERAPY: SYNERGISTIC STRATEGIES
Several combination therapies of autophagy modulating agents
have been examined for their efficacy to inhibit TC progression,
invasiveness, and metastatic disease.
Combination therapy: multiple targets within the PI3K/Akt/mTOR
pathway
BEZ235 is a dual PI3K/mTOR inhibitor that reduces PI3K and
mTOR kinase activity by competitive binding to the ATP-binding
cleft of these enzymes (153). BEZ235 effectively inhibited cell
proliferation in eight TC cell lines originating from four major
histological types (PTC, FTC, poorly differentiated TC, ATC) with
relatively low median effect doses (<44 nmol/L). In addition to
inhibiting cell cycle progression, BEZ235 caused apoptosis in two
out of six cell lines. Daily treatment in mice with 8505-C xenograft
tumors delayed tumor growth during the therapeutic period and
significantly degraded caspase-3, indicating that this compound
may induce apoptosis in vivo (154). However, reactivated tumor
growth observed after discontinuation of BEZ235 suggests that
prolonged treatment is necessary to maintain therapeutic effect.
However, BEZ235 was not able to repress p-Akt in all cell lines,
indicating that the compensatory activation of Akt by inhibiting
mTORC1 may still play a role (148). The novel allosteric Akt
inhibitor MK2206 could completely overrule the feedback acti-
vation of Akt from temsirolimus-induced mTOR suppression,
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and the two inhibitors synergistically inhibited TC cell growth
in OCUT1 and K1 cell lines (141).
Combination therapy: concomitant targeting PI3K/Akt/mTOR and
other pathways
The involvement of multiple signaling pathways in aggressive TC
suggests that it may be necessary to target several pathways simul-
taneously for effective treatment. Jin et al. demonstrated over 60%
growth inhibition with combined MEK and mTOR inhibition in
10 cell lines using the MEK inhibitor AZD6244 (ARRY-142886)
and mTOR inhibitor rapamycin (155). Recently, a combination
of AZD6244 and GDC0941, a novel PI3K inhibitor, led to syner-
gistic inhibition of TC cells that harbored genetic alterations in
MAPK and PI3K/AKT pathways. Exposure to the combination
of the compounds caused DNA fragmentations, which indicates
strong apoptosis (156). These proapoptotic effects are essential
since cell death is fundamental for eradication and hence cure
of cancer. Other combination therapy also includes blocking
VEGFR. RAF265 is an ATP-competitive pan RAF-inhibitor that
also inhibits VEGFR2. RAF265 and BEZ235 strongly inhibit tumor
growth, both in vitro and in vivo (157). The tested drug combina-
tion resulted in profound G1–G0 arrest and was associated with
consistent inhibition of targeted kinases. These preclinical stud-
ies provide further support that dual targeting of the MAPK and
PI3K pathways is more effective than targeting pathways indi-
vidually. Sorafenib is an oral KI with in vitro activity against
multiple targets, including RAF, RET, VEGFR1, and VEGFR2. An
ongoing phase-II trial (NCT01141309) assesses the combination
of sorafenib (400 mg twice a day) and everolimus (10 mg daily)
in progressive RAI-refractory TC, excluding ATC. The combina-
tion of sorafenib and everolimus shows promising results: partial
response rates were higher than those reported for sorafenib as a
single agent, with a partial response of 56% for non-medullary TC.
However, several grade-4 adverse events occurred possibly related
to the drug (158).
Other phase-II trials are investigating combination therapy of
everolimus and pasireotide, a novel somatostatin analog, in adults
with RAI refractory DTC (NCT01270321) and sorafenib com-
bined with temsirolimus in patients with TC of follicular cell origin
(e.g., PTC, FTC, Hurthle cell carcinoma) (NCT01025453). Fur-
thermore, although not yet investigated in TC, PI3k/Akt/mTOR
inhibitors can be combined with autophagy regulators: the PI3K–
mTOR inhibitor NVP-BEZ235 synergized with chloroquine to
induce apoptosis in glioma xenografts (159).
Combination therapy of PI3K/Akt/mTOR inhibitors with conventional
radiotherapy and chemotherapy
As mentioned before, PI3K/Akt/mTOR inhibitors may sensi-
tize TC cells to current therapy by, e.g., inducing redifferenti-
ation, as has been demonstrated for mTOR inhibition (160).
Furthermore, external radiotherapy and chemotherapy may be
used in extensively dedifferentiated TC. Chemotherapy options
include doxorubicin, docetaxel, or the combination of cisplatin
with doxorubicin for ATC. Several studies showed the syner-
gistic effect of mTOR inhibition with chemotherapeutic agents;
RAD001 (everolimus) sensitized PTC to doxorubicin and exter-
nal beam radiation in a synergistic fashion. Treatment with
20 nmol/L of RAD001 decreased the IC50 of doxorubicin by 48
and 38% in 8505-C and TPC-1 cells, respectively, and PTC cells
treated with RAD001 had a significant improvement in sen-
sitivity to various doses of radiation (113). Although not yet
approved for treating ATC, the combination therapy of BEZ235
and paclitaxel consistently demonstrated synergistic effects against
ATC in vitro (154). Interactions between BEZ235 and pacli-
taxel, irinotecan, and etoposide were determined by calculat-
ing the combination index by Chou–Talalay equation. Synergis-
tic effects were identified for the combination of BEZ235 and
paclitaxel in all used ATC lines. BEZ235 combined with irinote-
can also enhanced therapeutic efficacy, particularly when more
cells were affected. BEZ235 plus etoposide only slightly increased
cytotoxicity.
Moreover, a phase I study of daily everolimus plus low-dose
weekly cisplatin was performed in 30 patients with advanced solid
tumors not curable by surgery or radiation therapy, including
7 patients with TC (161). The phase II recommended dose is
everolimus 10 mg/day (days 1–21) and cisplatin 20 mg/m2 (days
1, 8, and 15) of a 28-day cycle, potentially leading to phase-II trials
combining everolimus and cisplatin for TC treatment.
TARGETING AUTOPHAGY MODULATORS IN THYROID CANCER: A
POTENTIAL REDIFFERENTIATION STRATEGY
Redifferentiation of TC cells that restores the sensitivity of the
tumor to RAI therapy is considered an important potential ther-
apeutic approach. Multiple strategies have been investigated for
their potential to induce redifferentiation of TC cells, ranging from
non-specific modalities such as retinoic acid and histone modi-
fication agents to treatment with specific oncogene-guided KIs,
including MAPK, MEK, mTOR, and Akt kinases. Of particular
interest to TC, inhibition of mTOR was demonstrated to increase
the capacity of physiological thyroid follicular cells to accumulate
iodine (35). Also PI3K-inhibition induced sodium iodine sym-
porter (NIS) expression in rat thyroid cells and human PTC (162).
By redifferentiation of TC cells, sensitivity to RAI therapy could
be restored. Ho et al. reported recently that a short course treat-
ment with selumetinib, a MAPK kinase inhibitor, resulted in an
increase of 131I uptake sufficient to enable RAI therapy in 12 of
20 patients (163). Moreover, a similar effect was observed in vitro
using an mTOR inhibitor. Pretreatment with rapamycin resulted
in three- to fivefold higher amounts of iodine accumulated in both
BC-PAP (PTC, BRAF V600 mutated) and FTC133 (FTC, PTEN
deficient) cell lines by restoring functional hNIS expression (160).
This study provides exciting new findings suggesting that mTOR
inhibition, potentially mediated by activation of autophagy, is a
promising new target for adjunctive therapy to improve the effi-
cacy of RAI treatment. It is indeed well described that autophagy
is also involved in mechanisms that determine the differentiation
status of TC cells; active autophagy contributes to maintaining
the differentiation status of TC cells after malignant transforma-
tion. In contrast, class I PI3K and mTOR block the autophagy
process and induce dedifferentiation of TC cells. These effects on
the differentiation status of tumor cells are exerted at the level of
the functionality of the iodine uptake machinery with NIS expres-
sion being one of the most prominently regulated proteins (35,
162). These findings indicate that autophagy is closely related to
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RAI sensitivity, which makes it a promising target to combat RAI
resistance. By reasoning, since also starvation is a potent inducer
of autophagy, patient starvation using a hypocaloric diet prior to
RAI treatment to induce local autophagy activity in thyroid cancer
cells might also increase the clinical response to RAI therapy.
CONCLUSION AND PERSPECTIVES
Remarkable progress in understanding the molecular pathogen-
esis of TC has been made in recent years. Significant knowledge
has been accumulated on the role of fundamental signaling path-
ways, such as the MAPK and the PI3K/Akt/mTOR pathways.
These pathways provide new targets for therapeutic agents. This
review focused on novel KI targeting the PI3K/Akt/mTOR and
autophagy pathway. Several new KI have been developed of which
dual mTORC1 and mTORC2 kinase inhibitors show great poten-
tial in different models, whereas classical mTOR inhibitors have
already been tested in clinical trials.
Notably, targeting the PI3K/Akt/mTOR pathway is more effec-
tive in TC cell lines with mutations in this pathway. PTEN loss of
function was, for example, identified as a predictor of sensitivity to
mTORC1 inhibition in several cancers (131). Therefore, the con-
cept of personalized medicine can be perfectly applied to patients
with TC considering the causal mutations in different pathways
described in various types of tumors. The characterization of the
mutational profile is critical in the design of treatment with either
single agent or combinational therapy and has been demonstrated
to lead to more effective treatment in pilot studies (164, 165). Con-
sistent with the idea of personalized medicine are findings that
combination therapy is more effective in RAI refractory tumors,
usually harboring mutations in several pathways, than targeting
pathways individually (154, 156). Ongoing trials combining KI
will reveal their efficacy in the future.
Although the role of autophagy in various settings in TC needs
to be further elucidated, autophagy regulators can be of great
potential. Induction of autophagy can sensitize thyroid tumor cells
to other therapies and plays a major role in the regulation of apop-
tosis. Combining novel KIs with other cytotoxic therapy is another
possible implementation in the development of novel therapeu-
tic strategies for TC, for example, the combination of everolimus
and chemotherapy. Moreover, the mTOR inhibitor rapamycin
has shown to increase the iodine uptake and may therefore be
a promising new target for adjunctive therapy for improving the
efficacy of RAI treatments. In the coming years, further develop-
ments in treatment options and selective application of available
agents are to be expected that will provide novel approaches to
more effectively treat TC.
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